Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Long-acting Injectable Antipsychotics in First-episode Schizophrenia.

Jeong HG, Lee MS.

Clin Psychopharmacol Neurosci. 2013 Apr;11(1):1-6. doi: 10.9758/cpn.2013.11.1.1. Epub 2013 Apr 24.

2.
3.

[Long acting injectable antipsychotics in the treatment of schizophrenia: a review of literature].

Graffino M, Montemagni C, Mingrone C, Rocca P.

Riv Psichiatr. 2014 May-Jun;49(3):115-23. doi: 10.1708/1551.16905. Review. Italian.

PMID:
25000887
4.
5.

Long-acting injectable antipsychotics: evidence of effectiveness and use.

Manchanda R, Chue P, Malla A, Tibbo P, Roy MA, Williams R, Iyer S, Lutgens D, Banks N.

Can J Psychiatry. 2013 May;58(5 Suppl 1):5S-13S. Review.

PMID:
23945067
6.

Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study.

Buckley PF, Schooler NR, Goff DC, Hsiao J, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz AJ, Miller del D, Severe JB, Wilson DR, Ames D, Bustillo J, Mintz J, Kane JM; PROACTIVE Study..

Schizophr Bull. 2015 Mar;41(2):449-59. doi: 10.1093/schbul/sbu067. Epub 2014 May 27.

7.

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life.

Montemagni C, Frieri T, Rocca P.

Neuropsychiatr Dis Treat. 2016 Apr 19;12:917-29. doi: 10.2147/NDT.S88632. eCollection 2016. Review.

8.

Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.

Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Borenstein M, Kane JM, Correll CU.

Schizophr Bull. 2014 Jan;40(1):192-213. doi: 10.1093/schbul/sbs150. Epub 2012 Dec 17.

9.
10.

Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review.

Gentile S.

Pharmacotherapy. 2013 Oct;33(10):1087-106. doi: 10.1002/phar.1313. Epub 2013 Jun 17. Review.

PMID:
23776129
11.

Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic.

Pilon D, Joshi K, Tandon N, Lafeuille MH, Kamstra RL, Emond B, Lefebvre P.

Patient Prefer Adherence. 2017 Mar 23;11:619-629. doi: 10.2147/PPA.S127623. eCollection 2017.

12.

Patient outcomes within schizophrenia treatment: a look at the role of long-acting injectable antipsychotics.

Bera RB.

J Clin Psychiatry. 2014;75 Suppl 2:30-3. doi: 10.4088/JCP.13065su1c.07. Review.

13.

Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics.

Heres S, Lambert M, Vauth R.

Eur Psychiatry. 2014 Nov;29 Suppl 2:1409-13. doi: 10.1016/S0924-9338(14)70001-X. Epub 2014 Nov 22. Review.

14.

[A history of antipsychotic long-acting injections in the treatment of schizophrenia].

Crocq MA.

Encephale. 2015 Feb;41(1):84-92. doi: 10.1016/j.encep.2014.12.002. Epub 2015 Jan 15. French.

PMID:
25598520
15.

Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review.

Taylor M, Ng KY.

Aust N Z J Psychiatry. 2013 Jul;47(7):624-30. doi: 10.1177/0004867412470010. Epub 2012 Dec 3. Review.

PMID:
23209308
16.

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence.

Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, Kane JM.

J Clin Psychiatry. 2016;77(suppl 3):1-24. doi: 10.4088/JCP.15032su1.

PMID:
27732772
17.
18.

Model of Management (Mo.Ma) for the patient with schizophrenia: crisis control, maintenance, relapse prevention, and recovery with long-acting injectable antipsychotics (LAIs).

Brugnoli R, Rapinesi C, Kotzalidis GD, Marcellusi A, Mennini FS, De Filippis S, Carrus D, Ballerini A, Francomano A, Ducci G, Del Casale A, Girardi P.

Riv Psichiatr. 2016 Mar-Apr;51(2):47-59. doi: 10.1708/2246.24194.

PMID:
27183509
19.

Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness.

Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L.

BMC Psychiatry. 2013 Dec 20;13:340. doi: 10.1186/1471-244X-13-340.

20.

[French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].

Samalin L, Abbar M, Courtet P, Guillaume S, Lancrenon S, Llorca PM.

Encephale. 2013 Dec;39 Suppl 4:189-203. doi: 10.1016/S0013-7006(13)70121-0. French.

PMID:
24373464

Supplemental Content

Support Center